<DOC>
	<DOCNO>NCT00422838</DOCNO>
	<brief_summary>Aim To evaluate effect peginterferon ribavirin therapy immune response chronic HCV genotype 1,2 3 patient , treatment . Background Treatment chronic hepatitis C ( HCV ) show remarkable success . However , genotype 1 patient reduced response rate . A good understanding improvement result consider great challenge . In chronically infected patient , HCV-specific immune response generally weak , narrowly focused , often dysfunctional . The presence HCV-specific cell suppress immune response ( regulatory T-lymphocytes=Treg ) able suppress immune response . These Treg possibly responsible impaired immune response . Previous study indicate increased Treg frequency activity immune regulate mechanism , locally liver , result HCV re-infection . Hence , Data highlight importance monitoring intrahepatic immune response addition peripheral immune response . Using minimally-invasive technique fine-needle aspiration biopsy ( FNAB ) , possible obtain safe frequent liver sample monitor local antiviral immune response chronic HCV patient antiviral therapy . Rationale hypothesis study Our previous study current literature support concept Treg may contribute HCV persistence suppress HCV-spec immune response . The current study design examine peginterferon ribavirin therapy affect activity Treg DC , result enhance HCV-specific immune response . Design Single centre , translational observational open label study one arm 20 genotype 1 patient one arm 7 genotype 2/3 patient .</brief_summary>
	<brief_title>Study Investigating Immunological Effects Treatment Chronic Hepatitis C Patients .</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<criteria>Male female patient 1870 year age , evidence chronic hepatitis C Genotype 1,2 3 infection . No previous treatment , peginterferon conventional interferon plus ribavirin combination therapy . Indication antiviral therapy hepatitis C accord current clinical guideline . Written informed consent . History evidence severe illness , malignancy condition would make patient , opinion investigator , unsuitable study . Presence contraindication antiviral therapy peginterferon ribavirin .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>Liver</keyword>
	<keyword>immunology</keyword>
	<keyword>regulation</keyword>
	<keyword>Genotype 1,2,3</keyword>
	<keyword>Treatment</keyword>
	<keyword>Chronic</keyword>
	<keyword>Pegylated interferon</keyword>
	<keyword>Ribavirin</keyword>
</DOC>